Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
Understanding of the natural history and basic biology of hepatitis B virus (HBV) has increased greatly in recent years. In view of this, the following are reviewed here: (a) recent advances in HBV biology pertinent to the rheumatic disease population; (b) the risks of HBV reactivation in patients with rheumatic disease undergoing immunosuppression; and (c) potential strategies to manage these risks.
Calabrese
L H
LH
Department of Rheumatic and Immunological Disease, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA. calabrl@ccf.org
Zein
N N
NN
Vassilopoulos
D
D
D018501:Antirheumatic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000150:complications / Q000209:etiology* / Q000517:prevention & control; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016867:Immunocompromised Host; D008099:Liver / Q000276:immunology / Q000821:virology; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000276:immunology*; D014775:Virus Activation
D018501:Antirheumatic Agents; D000998:Antiviral Agents